- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07570160
Intranasal Dexmedetomidine or Esketamine for Negative Postoperative Behavioral Changes in Children (PEDI-NPOBCs)
Exploring the Association of Perioperative Electroencephalographic Changes Following Preoperative Intranasal Dexmedetomidine or Esketamine With Negative Postoperative Behavioral Changes in Children Undergoing Day Surgery
The goal of this clinical trial is to learn whether intranasal dexmedetomidine or esketamine given before anesthesia can reduce negative postoperative behavioral changes in children undergoing day surgery. Negative postoperative behavioral changes may include anxiety, sleep problems, nightmares, irritability, or other unusual behaviors after surgery. This study will also examine whether changes in brain wave patterns during the perioperative period are related to these behavioral changes.
The main questions this study aims to answer are:
Does intranasal dexmedetomidine reduce negative postoperative behavioral changes in children after day surgery? Does intranasal esketamine reduce negative postoperative behavioral changes in children after day surgery? Are perioperative electroencephalographic (EEG) features associated with negative postoperative behavioral changes? Researchers will compare intranasal dexmedetomidine, intranasal esketamine, and normal saline to see whether these treatments differ in their effects on postoperative behavior and perioperative EEG features.
Participants will be randomly assigned to receive intranasal dexmedetomidine, intranasal esketamine, or intranasal normal saline about 30 minutes before anesthesia. They will receive routine perioperative monitoring, including EEG monitoring during surgery and recovery. They will also be assessed for sedation, pain, and emergence delirium. Follow-up assessments of postoperative behavioral changes will be completed on postoperative days 3, 7, and 28.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This multicenter, prospective, randomized, double-blind, controlled clinical trial will evaluate whether preoperative intranasal dexmedetomidine or esketamine can reduce negative postoperative behavioral changes in children undergoing day surgery under general anesthesia. The study will also explore whether perioperative electroencephalographic (EEG) features are associated with these behavioral changes and may help explain the effects of the study drugs.
A total of 342 children undergoing elective day surgery will be enrolled across four centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to receive intranasal dexmedetomidine 2.0 micrograms/kg, intranasal esketamine 1.0 mg/kg, or an equal volume of normal saline approximately 30 minutes before induction of anesthesia. Study medications will be prepared in identical, unlabeled nasal spray devices to maintain blinding. Participants, investigators, and outcome assessors will remain unaware of treatment assignment throughout the study.
After study drug administration, participants will undergo routine perioperative monitoring. Sedation will be assessed before surgery. During anesthesia and recovery, EEG and other perioperative clinical data will be collected. Postoperative assessments will include pain and emergence delirium. Negative postoperative behavioral changes will be evaluated on postoperative days 3, 7, and 28. The primary outcome is the incidence of negative postoperative behavioral changes on postoperative day 7. Secondary analyses will assess behavioral outcomes at postoperative days 3 and 28 and examine the relationship between perioperative EEG patterns and postoperative behavioral changes.
This study is designed to provide evidence on the comparative effects of intranasal dexmedetomidine and esketamine on postoperative behavioral recovery in children undergoing day surgery and to identify perioperative EEG markers that may be associated with adverse behavioral outcomes.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Li Zhang, Doctoral degree
- Número de telefone: +86 138 1540 6629
- E-mail: drzhangli@njmu.edu.cn
Estude backup de contato
- Nome: Fei Sun, Master's degree
- Número de telefone: +86 181 0061 9994
- E-mail: drsunfei89@163.com
Locais de estudo
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Children's Hospital of Nanjing Medical University
-
Contato:
- Medical Ethics Committee of Children's Hospital of Nanjing Med
- Número de telefone: +86 189 5176 2937
- E-mail: drsunfei@njmu.edu.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Children aged 2 to 12 years.
- Scheduled to undergo elective day surgery under general anesthesia.
- ASA (American Society of Anesthesiologists) physical status I to III.
Exclusion Criteria:
- Congenital diseases or severe liver or kidney dysfunction.
- History of allergic reactions to study drugs.
- Neuromuscular diseases, cerebral palsy, epilepsy.
- Other psychiatric or neurological disorders.
- Body mass index (BMI) ≥ 30 kg/m².
- Severe upper respiratory tract infections prior to surgery.
- Use of sedatives or analgesics within 48 hours before surgery.
- Exposure to major life stressors within 1 month before surgery (e.g., family separation, death of a parent).
- Refusal to participate or failure to obtain consent from the child's legal guardian.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intranasal Dexmedetomidine
Participants receive intranasal dexmedetomidine 2.0 micrograms/kg approximately 30 minutes before induction of general anesthesia.
|
Intranasal dexmedetomidine 2.0 micrograms/kg administered once approximately 30 minutes before induction of general anesthesia.
Outros nomes:
|
|
Experimental: Intranasal Esketamine
Participants receive intranasal esketamine 1.0 mg/kg approximately 30 minutes before induction of general anesthesia.
|
Intranasal esketamine 1.0 mg/kg administered once approximately 30 minutes before induction of general anesthesia.
Outros nomes:
|
|
Comparador de Placebo: Normal Saline Control
Participants receive an equal volume of intranasal normal saline approximately 30 minutes before induction of general anesthesia.
|
Intranasal normal saline of equal volume administered once approximately 30 minutes before induction of general anesthesia.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 7
Prazo: Postoperative Day 7
|
Incidence of negative postoperative behavioral changes assessed using the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS).
|
Postoperative Day 7
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 3
Prazo: Postoperative Day 3
|
Incidence of negative postoperative behavioral changes assessed using the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS).
|
Postoperative Day 3
|
|
Incidence of Negative Postoperative Behavioral Changes on Postoperative Day 28
Prazo: Postoperative Day 28
|
Incidence of negative postoperative behavioral changes assessed using the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS).
|
Postoperative Day 28
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sedation Score 30 Minutes After Study Drug Administration
Prazo: 30 minutes after study drug administration
|
Sedation level assessed 30 minutes after study drug administration using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale.
Scores range from 0 to 5, with 0 indicating no response to painful stimulus and 5 indicating fully alert.
Higher scores indicate better alertness and less sedation.
|
30 minutes after study drug administration
|
|
Postoperative Pain Score
Prazo: At the time of emergence in the post-anesthesia care unit
|
Pain intensity assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale.
Scores range from 0 to 10, with higher scores indicating worse pain.
|
At the time of emergence in the post-anesthesia care unit
|
|
Emergence Delirium Score
Prazo: After emergence in the post-anesthesia care unit
|
Emergence delirium assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale.
Scores range from 0 to 20, with higher scores indicating worse emergence delirium.
|
After emergence in the post-anesthesia care unit
|
|
Intraoperative Electroencephalographic Parameters Before Emergence Description
Prazo: From induction of anesthesia until before emergence
|
Electroencephalographic parameters derived from raw intraoperative electroencephalography recordings obtained from after induction of anesthesia until before emergence.
Reported values will be summarized from the recorded electroencephalographic data.
|
From induction of anesthesia until before emergence
|
|
Incidence of Perioperative Adverse Events
Prazo: From administration of study drug until discharge from the post-anesthesia care unit, assessed up to the maximum expected PACU stay (varies by individual, typically 1-4 hours)
|
Incidence of perioperative adverse events, including nausea, vomiting, allergic reactions, emergence delirium, and other adverse behavioral or physiological events occurring in children during the immediate postoperative period.
All adverse events are continuously monitored and recorded by trained clinical staff using standardized observation procedures and behavioral scales (e.g., PAED scale for emergence delirium).
The observation period includes the entire post-anesthesia care unit stay until the child meets discharge criteria.
|
From administration of study drug until discharge from the post-anesthesia care unit, assessed up to the maximum expected PACU stay (varies by individual, typically 1-4 hours)
|
|
Emergence Time
Prazo: In the post-anesthesia care unit on the day of surgery
|
Time from discontinuation of anesthesia to emergence.
|
In the post-anesthesia care unit on the day of surgery
|
|
Postoperative Time to Discharge
Prazo: From end of surgery to discharge on the day of surgery
|
Time from the end of surgery to hospital discharge.
|
From end of surgery to discharge on the day of surgery
|
|
Parental Satisfaction Score Assessed by the Pediatric Anesthesia Parent Satisfaction (PAPS) Questionnaire
Prazo: On the day of surgery before discharge
|
Parental satisfaction with perioperative management assessed on the day of surgery before discharge using the Pediatric Anesthesia Parent Satisfaction (PAPS) questionnaire.
The questionnaire includes 15 items, and total scores range from 15 to 75, calculated as the sum of all item scores.
Higher scores indicate greater parental satisfaction.
|
On the day of surgery before discharge
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: fei sun, Master's, Children's Hospital of Nanjing Medical University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Complicações pós-operatórias
- Processos Patológicos
- Confusão
- Manifestações Neurocomportamentais
- Distúrbios Neurocognitivos
- Delírio
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Delírio de emergência
- Transtornos Mentais, Desordem Mental
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Preparações farmacêuticas
- Azoles
- Imidazoles
- Produtos químicos inorgânicos
- Compostos de cloro
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Compostos de sódio
- Cloretos
- Ácido clorídrico
- Esketamina
- Dexmedetomidina
- Solução salina
- Cloreto de sódio
Outros números de identificação do estudo
- 202512066-2
- SWYY2025002065 (Número de outro subsídio/financiamento: ISEFC, China)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .